Literature DB >> 20970309

Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.

S Saigusa1, K Tanaka, Y Toiyama, T Yokoe, Y Okugawa, Y Koike, H Fujikawa, Y Inoue, C Miki, M Kusunoki.   

Abstract

AIMS: The mechanism of distant recurrence in rectal cancer after preoperative chemoradiotherapy (CRT) has yet to be fully elucidated. Further improvements in survival rates cannot be achieved without decreasing distant recurrence after preoperative CRT. Recently, it was reported that hypoxic conditions were correlated with cancer stem cell generation. Therefore, we investigated the correlation between the expression of CD133 and hypoxia inducible factor-1α (HIF-1α), and their association with clinical outcome.
MATERIALS AND METHODS: Fifty-two patients with rectal cancer underwent preoperative CRT. Residual cancer cells after CRT were obtained from formalin-fixed paraffin-embedded specimens using micro-dissection. The expression levels of CD133 (PROM1) and HIF-1α genes were measured using real-time reverse transcription polymerase chain reaction. The correlation between expression and irradiation was evaluated using colon cancer cell lines. Immunohistochemical staining of these proteins after CRT was also investigated.
RESULTS: We observed a significant inverse correlation between the gene expression of CD133 (PROM1) and HIF-1α genes in residual cancer cells after CRT. Elevated CD133 gene expression was associated with distant recurrence and poor recurrence-free survival. Elevated HIF-1α gene expression was associated with poor overall survival. In vitro, the change in gene expression levels after irradiation showed inverse patterns. Immunohistochemical analyses showed that residual cancer cells strongly expressed CD133 and lacked HIF-1α expression.
CONCLUSION: Our results suggest that CD133 and HIF-1α expression is associated with tumour re-growth and distant recurrence after CRT. These results may assist in clarifying the development of future cancer therapeutics in rectal cancer patients undergoing preoperative CRT.
Copyright © 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970309     DOI: 10.1016/j.clon.2010.09.012

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  14 in total

1.  Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis.

Authors:  Jin-Hai Zhai; Wen-Chao Gu; Xiao-Lin Xu; Jiang Wu; Xue-Jun Hu; Ke-Zhu Hou
Journal:  Tumour Biol       Date:  2014-10-07

2.  Single nucleotide polymorphisms in the HIF-1α gene and chemoradiotherapy of locally advanced rectal cancer.

Authors:  Birgitte Mayland Havelund; Karen-Lise Garm Spindler; John Ploen; Rikke Fredslund Andersen; Anders Jakobsen
Journal:  Oncol Lett       Date:  2012-07-31       Impact factor: 2.967

3.  Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors.

Authors:  Chih-Hung Lin; Wan-Tzu Chen; Chia-Hsing Liu; Hung-Pei Tsai; Chun-Chieh Wu; Chee-Yin Chai
Journal:  Virchows Arch       Date:  2012-03-28       Impact factor: 4.064

4.  Colorectal Cancer Stem Cells: Biology and Therapeutic Implications.

Authors:  Brian J Wilson; Tobias Schatton; Markus H Frank; Natasha Y Frank
Journal:  Curr Colorectal Cancer Rep       Date:  2011-06

5.  Prognostic value of HIF-1α in digestive system malignancies: evidence from a systematic review and meta-analysis.

Authors:  Mohammad-Hassan Arjmand; Ali Moradi; Hamid-Reza Rahimi; Ali Es-Haghi; Abolfazl Akbari; Mohammad Reza Hadipanah; Jalil Afshar; Hassan Mehrad-Majd
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

Review 6.  CD133: a cancer stem cells marker, is used in colorectal cancers.

Authors:  Fei Ren; Wei-Qi Sheng; Xiang Du
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

7.  Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo.

Authors:  Susann Peickert; Julia Waurig; Claudia Dittfeld; Antje Dietrich; Yvette Garbe; Lydia Kabus; Michael Baumann; Marian Grade; Thomas Ried; Leoni A Kunz-Schughart
Journal:  Lab Invest       Date:  2012-09-10       Impact factor: 5.662

Review 8.  CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.

Authors:  Shicai Chen; Xinming Song; Zhihui Chen; Xinxin Li; Mingzhe Li; Haiying Liu; Jianchang Li
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

9.  Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  J Cell Mol Med       Date:  2013-01-10       Impact factor: 5.310

10.  Prognostic value and clinicopathological differences of HIFs in colorectal cancer: evidence from meta-analysis.

Authors:  Zhigang Chen; Xin He; Wenjie Xia; Qi Huang; Zhigang Zhang; Jun Ye; Chao Ni; Pin Wu; Dang Wu; Jinghong Xu; Fuming Qiu; Jian Huang
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.